CL2023001195A1 - Compuestos bicíclicos y usos de los mismos para el tratamiento de enfermedades. - Google Patents
Compuestos bicíclicos y usos de los mismos para el tratamiento de enfermedades.Info
- Publication number
- CL2023001195A1 CL2023001195A1 CL2023001195A CL2023001195A CL2023001195A1 CL 2023001195 A1 CL2023001195 A1 CL 2023001195A1 CL 2023001195 A CL2023001195 A CL 2023001195A CL 2023001195 A CL2023001195 A CL 2023001195A CL 2023001195 A1 CL2023001195 A1 CL 2023001195A1
- Authority
- CL
- Chile
- Prior art keywords
- diseases
- treatment
- bicyclic compounds
- compounds
- compositions
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 210000003494 hepatocyte Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063108660P | 2020-11-02 | 2020-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001195A1 true CL2023001195A1 (es) | 2023-10-20 |
Family
ID=81384389
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001195A CL2023001195A1 (es) | 2020-11-02 | 2023-04-26 | Compuestos bicíclicos y usos de los mismos para el tratamiento de enfermedades. |
| CL2024000340A CL2024000340A1 (es) | 2020-11-02 | 2024-02-02 | Compuestos bicíclicos y usos de los mismos para el tratamiento de enfermedades |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024000340A CL2024000340A1 (es) | 2020-11-02 | 2024-02-02 | Compuestos bicíclicos y usos de los mismos para el tratamiento de enfermedades |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240025903A1 (https=) |
| EP (1) | EP4236944A4 (https=) |
| JP (1) | JP2023550543A (https=) |
| KR (1) | KR20230104191A (https=) |
| CN (2) | CN119684295A (https=) |
| AR (1) | AR124637A1 (https=) |
| AU (1) | AU2021371026A1 (https=) |
| CA (1) | CA3196582A1 (https=) |
| CL (2) | CL2023001195A1 (https=) |
| IL (1) | IL302465A (https=) |
| MX (1) | MX2023004942A (https=) |
| WO (1) | WO2022094400A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240121239A (ko) * | 2021-12-17 | 2024-08-08 | 아티라 파마, 인코포레이티드 | 질환 치료를 위한 이환식 화합물의 용도 |
| EP4518864A1 (en) * | 2022-05-04 | 2025-03-12 | Athira Pharma, Inc. | Methods of treating neuropathies |
| JP2025515045A (ja) * | 2022-05-04 | 2025-05-13 | アティラ・ファーマ・インコーポレイテッド | 神経炎症病態を治療する方法 |
| EP4618996A1 (en) | 2022-11-18 | 2025-09-24 | Athira Pharma, Inc. | Methods of treating inflammatory conditions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184223B1 (en) * | 1995-10-27 | 2001-02-06 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
| AU2003284120A1 (en) * | 2002-10-17 | 2004-05-04 | Myriad Genetics, Inc. | Reverse-turn mimetics and composition and methods relating thereto |
| US7192976B2 (en) * | 2002-12-21 | 2007-03-20 | Angion Biomedica Corporation | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| AU2005289560A1 (en) * | 2004-09-28 | 2006-04-06 | Angion Biomedica Corp. | Small molecule modulators of cytokine activity |
| US7879898B1 (en) * | 2006-02-14 | 2011-02-01 | Angion Biomedica Corp. | Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease |
| EP1947085A1 (en) * | 2007-01-19 | 2008-07-23 | Laboratorios del Dr. Esteve S.A. | Substituted indole sulfonamide compounds, their preparation and use as medicaments |
| CN102186853A (zh) * | 2008-10-14 | 2011-09-14 | 株式会社棱镜生物实验室 | 治疗癌症α-螺旋模拟物 |
| WO2014025832A1 (en) * | 2012-08-06 | 2014-02-13 | University Of Southern California | Wnt modulators for the protection, mitigation and treatment of radiation injury |
| WO2017047762A1 (ja) * | 2015-09-18 | 2017-03-23 | 国立大学法人鳥取大学 | 低分子化合物による癌と線維化の抑制と再生促進の効果 |
-
2021
- 2021-11-01 CN CN202411623883.1A patent/CN119684295A/zh active Pending
- 2021-11-01 MX MX2023004942A patent/MX2023004942A/es unknown
- 2021-11-01 EP EP21887720.7A patent/EP4236944A4/en active Pending
- 2021-11-01 AR ARP210103033A patent/AR124637A1/es unknown
- 2021-11-01 WO PCT/US2021/057563 patent/WO2022094400A1/en not_active Ceased
- 2021-11-01 US US18/032,918 patent/US20240025903A1/en active Pending
- 2021-11-01 IL IL302465A patent/IL302465A/en unknown
- 2021-11-01 CN CN202180079749.8A patent/CN116568301A/zh active Pending
- 2021-11-01 KR KR1020237018061A patent/KR20230104191A/ko active Pending
- 2021-11-01 CA CA3196582A patent/CA3196582A1/en active Pending
- 2021-11-01 JP JP2023551946A patent/JP2023550543A/ja active Pending
- 2021-11-01 AU AU2021371026A patent/AU2021371026A1/en active Pending
-
2023
- 2023-04-26 CL CL2023001195A patent/CL2023001195A1/es unknown
-
2024
- 2024-02-02 CL CL2024000340A patent/CL2024000340A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4236944A4 (en) | 2024-09-04 |
| TW202233622A (zh) | 2022-09-01 |
| US20240025903A1 (en) | 2024-01-25 |
| WO2022094400A1 (en) | 2022-05-05 |
| MX2023004942A (es) | 2023-07-06 |
| EP4236944A1 (en) | 2023-09-06 |
| JP2023550543A (ja) | 2023-12-01 |
| CA3196582A1 (en) | 2022-05-05 |
| AR124637A1 (es) | 2023-04-19 |
| CN116568301A (zh) | 2023-08-08 |
| AU2021371026A9 (en) | 2024-04-18 |
| KR20230104191A (ko) | 2023-07-07 |
| IL302465A (en) | 2023-06-01 |
| CL2024000340A1 (es) | 2024-08-16 |
| CN119684295A (zh) | 2025-03-25 |
| AU2021371026A1 (en) | 2023-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024000340A1 (es) | Compuestos bicíclicos y usos de los mismos para el tratamiento de enfermedades | |
| CO2021007993A2 (es) | Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina | |
| MX2021007468A (es) | Compuestos que participan en la union cooperativa y usos de los mismos. | |
| ECSP20018487A (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| CO2022010547A2 (es) | Compuestos y usos de los mismos | |
| DOP2020000040A (es) | Compuestos espirocíclicos y sus métodos de preparación y uso | |
| PA8570701A1 (es) | Compuestos que modulan la actividad de ppar y procedimientos para su preparacion | |
| DOP2024000028A (es) | Degradadores bifuncionales de quinasas asociadas al receptor de interleucina 1 y usos terapéuticos de los mismos | |
| MX2020012158A (es) | Inhibidores de magl. | |
| MX2022000550A (es) | Imidazopirimidinas como inhibidores de eed y uso de estas. | |
| NI202000014A (es) | Compuestos espirocíclicos y sus métodos de preparación y uso | |
| MX350890B (es) | Agentes para tratar trastornos que implican la modulación de receptores de rianodina. | |
| MX2022006862A (es) | Inhibidores duales de magl y faah. | |
| CO2023010940A2 (es) | Compuestos moduladores de gcn2 y usos de los mismos | |
| CL2021001656A1 (es) | Compuestos de imidazopiridina e imidazopiridina y sus usos. | |
| CL2021002521A1 (es) | Compuestos heteocíclicos y sus usos. | |
| MX2024013040A (es) | Pirfenidona enriquecida con deuterio y metodos para su uso | |
| CL2024003870A1 (es) | Compuestos de degradación de wee1 y usos de los mismos | |
| DOP2022000127A (es) | Triterpenoides sintéticos con sustituyentes a base de nitrógeno en c-17 y métodos de uso de los mismos. | |
| MX2018009189A (es) | Compuestos de anillo de siete miembros de pirimidina. | |
| CL2025003186A1 (es) | Moduladores de nk3 y usos de los mismos. | |
| CL2024001748A1 (es) | Usos de compuestos biciclicos para el tratamiento de enfermedades. | |
| CL2022002589A1 (es) | Tratamiento de trastornos respiratorios | |
| CO2023003078A2 (es) | Compuestos como moduladores de bis-fosfoglicerato mutasa para el tratamiento de la anemia de células falciforme | |
| ECSP22019177A (es) | Proteínas de fusión nkg2d y sus usos |